Public, NASDAQ:PANC
NASDAQ Global Market
2008-07-02 15:01:16 - www.companiesandmarkets.com adds new report - Panacos Pharmaceuticals Inc - Premium Company Profile
Date: Wed, 02 Jul 2008 13:15:00 GMT
Tags:
2008-07-02 15:01:16 - www.companiesandmarkets.com adds new report - Panacos Pharmaceuticals Inc - Premium Company Profile
PR-Inside.com (Pressemitteilung) - Jul 2, 2008
PR-Inside.com (Pressemitteilung) - Jul 2, 2008
Panacos Pharmaceuticals is a development stage biotechnology company specialized in developing antiviral products for the treatment of patients with HIV infection.The company ' s lead drug candidate ...
Feuerstein's Biotech-Stock Mailbag: Panacos
Date: Fri, 20 Jun 2008 16:19:24 GMT
Tags:
Feuerstein's Biotech-Stock Mailbag: Panacos
TheStreet.com - Jun 20, 2008
TheStreet.com - Jun 20, 2008
The Biotech Mailbag is open.Our first email comes from Joe B . , who asks for my thoughts on Panacos Pharmaceuticals PANC.Joe's email has been sitting in the mailbag for a long while , but it's ...
Biotech-Stock Mailbag: Panacos, Indevus - TheStreet.comPanacos Announces Results of Bevirimat Prospective Study, Which Confirm Patient Response Predictors
Date: Wed, 18 Jun 2008 11:45:30 GMT
Tags:
Panacos Announces Results of Bevirimat Prospective Study, Which Confirm Patient Response Predictors
RedOrbit - Jun 18, 2008
RedOrbit - Jun 18, 2008
Panacos Pharmaceuticals , Inc . ( NASDAQ : PANC ) today announced the completion of a Phase 2b prospective study of bevirimat in treatment - experienced and treatment - naive patients that confirms ...
Panacos Pharma reports Favorable Results From Bevirimat Prospective Study - Quick Facts
Date: Tue, 17 Jun 2008 20:33:19 GMT
Tags:
Panacos Pharma reports Favorable Results From Bevirimat Prospective Study - Quick Facts
RTT News - Jun 17, 2008
RTT News - Jun 17, 2008
( RTTNews ) - Tuesday , Panacos Pharmaceuticals Inc . ( PANC : News , Chart , Quote ) reported that the Phase 2b prospective study of the company's HIV maturation inhibitor , bevirimat in treatment ...
Panacos Announces Results of Bevirimat Prospective Study, which Confirm Patient Response Predictors
Date: Tue, 17 Jun 2008 20:11:53 GMT
Tags:
Panacos Announces Results of Bevirimat Prospective Study, which Confirm Patient Response Predictors
Business Wire (press release) - Jun 17, 2008
Business Wire (press release) - Jun 17, 2008
WATERTOWN , Mass . - - ( BUSINESS WIRE ) - - Panacos Pharmaceuticals , Inc . ( NASDAQ : PANC ) today announced the completion of a Phase 2b prospective study of bevirimat in treatment - experienced ...
Feuerstein's Biotech-Stock Mailbag: Panacos (at TheStreet.com)
Date: Fri, 20 Jun 2008 15:06:14 Etc/GMT
Tags:
Panacos Pharmaceuticals, Inc. R&D Day Call scheduled for 12:00 pm ET today (CCBN)
Date: Wed, 18 Jun 2008 16:00:00 Etc/GMT
Tags:
PANACOS PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (EDGAR Online)
Date: Tue, 17 Jun 2008 21:02:58 Etc/GMT
Tags:
Panacos Announces Results of Bevirimat Prospective Study, which Confirm Patient Response Predictors (Business Wire)
Date: Tue, 17 Jun 2008 20:00:00 Etc/GMT
Tags:
WATERTOWN, Mass.----Panacos Pharmaceuticals, Inc. today announced the completion of a Phase 2b prospective study of bevirimat in treatment-experienced and treatment-naïve patients that confirms the recently discovered factors that predict response to bevirimat, its lead HIV maturation inhibitor.
PANACOS PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (EDGAR Online)
Date: Wed, 11 Jun 2008 13:09:13 Etc/GMT
Tags: